An elderly American man has become completely blind after he was prescribed to take Ozempic to manage his type 2 diabetes.

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic neuropathy ... with more severe visual field impairment linked to ...

Although only association and not causality can be inferred, this study showed that, among patients who had diabetes, an elevated risk of NAION was associated with semaglutide use compared with ...

The lawsuits allege that Ozempic causes a rare eye condition called NAION, or non-arteritic anterior ischemic optic neuropathy, which is akin to an eye stroke. All but one of the cases were filed ...

The brain then processes the visual information to create the images we see. Depending on the extent of injury, a damaged optic nerve can range from a reduced field of vision to total blindness.

Considering taking supplements to treat ischemic optic neuropathy? Below is a list of common natural remedies used to treat or reduce the symptoms of ischemic optic neuropathy. Follow the links to ...

Nonarteritic anterior ischemic optic neuropathy—known as NAION—can ... controversial—swing that is emblematic of the growing field of science devoted to untangling and reversing what is ...

An ophthalmologist urged her to rush to the emergency room for an MRI, where she was diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) in her right eye, she said. Things got ...

Among 11,558 semaglutide-related reports, researchers identified 417 cases specifically related to visual impairment, retinopathy, or ischemic optic neuropathy. The researchers observed a more ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...